Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Moderna Inc. has landed its second product approval from the U.S. Food and Drug Administration after its COVID-19 vaccine. The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to have its vaccine for respiratory syncytial ...
Sanofi SNY and Regeneron REGN announced that the FDA extended the review period for a regulatory filing seeking label expansion for their blockbuster drug Dupixent in chronic obstructive pulmonary ...
A man with a suspended license joined his court Zoom call while driving, astonishing the judge and his legal team.
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that ...
Reports of a rare nervous system disorder are "more common than expected" in older U.S. adults who got the new RSV vaccines.